2020
DOI: 10.1111/jpc.14698
|View full text |Cite
|
Sign up to set email alerts
|

Standard management protocol to improve the short‐term outcome of biliary atresia

Abstract: Aim This study compared the outcomes of patients with biliary atresia (BA) treated according to a standardised protocol with historical patients. Methods This is a single‐centred retrospective study of BA patients treated from 1980 to 2016. A standardised treatment protocol was established since 2008 regarding peri‐operative management. The outcomes being compared between the two groups (Groups I and II = before and after 2008, respectively) were jaundice clearance (JC), incidence of recurrent cholangitis, hos… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 26 publications
0
4
0
Order By: Relevance
“…Recurrent cholangitis is another significant factor which negatively affects native liver survival. Thus, post-KPE patients who present with fever and cholangitis should be promptly treated with antibiotics 163 , 164 .…”
Section: Hepatobiliarymentioning
confidence: 99%
“…Recurrent cholangitis is another significant factor which negatively affects native liver survival. Thus, post-KPE patients who present with fever and cholangitis should be promptly treated with antibiotics 163 , 164 .…”
Section: Hepatobiliarymentioning
confidence: 99%
“…BA has caused suffering in thousands of families with disease incidences of 0.05 to 0.14% in live births. Although Kasai portoenterostomy can effectively improve early clinical outcomes, over 70% of BA patients have to ultimately undergo liver transplantation to survive [ 93 ]. Its etiology remains to be fully revealed, but it is known that genetic mutations, exposure to hepatotoxin, and infection by viruses could contribute to the cause of BA [ 92 ].…”
Section: Biomedical Applications Of Bioengineering Liver Organoidsmentioning
confidence: 99%
“…In humans, management after a Kasai operation consists of UDCA for at least 3 months, intravenous antibiotics for at least 2 weeks or longer and fat‐soluble vitamin supplementation (Chung et al . 2020). The clinical benefit of high‐dose glucocorticoid administration for 6 weeks post‐operatively is controversial (Bezerra et al .…”
Section: Congenital Biliary Disordersmentioning
confidence: 99%
“…2014, Chung et al . 2020). Eventually, the majority of humans with EHBA will require a liver transplant in their lives.…”
Section: Congenital Biliary Disordersmentioning
confidence: 99%